BH02 Overcoming Genetic Drivers in Alopecia Areata: Hair Regrowth in a Patient with the AIRE Gene Mutation Treated with Ruxolitinib

This study reports on a 20-year-old woman with alopecia universalis associated with APECED due to a biallelic AIRE gene mutation, who achieved complete hair regrowth after 9 months of treatment with ruxolitinib, a Janus kinase inhibitor. The patient initially presented with patchy hair loss, which progressed despite previous treatments. Ruxolitinib was administered primarily to address her chronic inflammatory demyelinating polyneuropathy (CIDP), but it also resulted in significant hair regrowth and improved quality of life. This case underscores the potential of ruxolitinib in treating severe alopecia areata linked to genetic mutations.